Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gregory Hooks

Internal Medicine Columbia, SC Medical Doctor

NPI 1629037320 CMS profile 254577

1750 Laurel Street, Columbia, SC 29201

Open in the dashboard

General payments

$6,791

406 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gregory Hooks of Columbia, SC is reported in the CMS Open Payments database as having received $6,791 across 406 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,918 105
2024 General $1,776 98
2023 General $857 52
2022 General $590 34
2020 General $326 23
2019 General $1,324 94

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Hooks
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Gregory Hooks were reported at $1,918. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Gregory Hooks Internal Medicine median Middle half National median
2019 $1,324 $159 $48–$570 $163
2020 $326 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $590 $141 $42–$496 $149
2023 $857 $149 $45–$519 $160
2024 $1,776 $154 $47–$537 $164
2025 $1,918 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $837 50 payments
  2. Lilly USA, LLC $801 57 payments
  3. Novo Nordisk Inc $702 44 payments
  4. Pfizer Inc. $567 39 payments
  5. AbbVie, Inc. $534 46 payments
  6. Amgen Inc. $500 25 payments
  7. Dexcom, Inc. $493 13 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $298 19 payments
  9. Exact Sciences Corporation $173 10 payments
  10. Abbott Laboratories $171 9 payments
  11. Other $1,715 94 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,791 406 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $556 32 payments
  2. Dexcom G6 Transmitter $493 13 payments
  3. MOUNJARO $479 31 payments
  4. Ozempic $434 26 payments
  5. RYBELSUS $347 20 payments
  6. Repatha $320 15 payments
  7. ZEPBOUND $309 19 payments
  8. Otezla $295 13 payments
  9. NURTEC ODT $259 14 payments
  10. UBRELVY $238 20 payments
  11. Other $5,807 379 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 123 drugs

Part D claims

8,081

Median for Internal Medicine: 777

Drug cost

$730,730

Median for Internal Medicine: $73,373

Branded share of claims

20.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 126 $186,460
Mounjaro Tirzepatide Brand 73 $119,790
Eliquis Apixaban Brand 54 $58,477
Jardiance Empagliflozin Brand 56 $58,302
Synjardy Xr Empagliflozin/Metformin Hcl Brand 56 $44,546
Farxiga Dapagliflozin Propanediol Brand 42 $42,058
Trulicity Dulaglutide Brand 17 $25,627
Januvia Sitagliptin Phosphate Brand 15 $23,452
Xarelto Rivaroxaban Brand 20 $22,060
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 74 $14,419

The 10 drugs with the highest cost, of 123 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$202,075

Of which drugs: $47,403

Medicare patients

439

Average age 74

Services billed

4,209

192 women, 247 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 42%
Diabetes 39%
Arthritis 36%
Ischemic heart disease 32%
Depression 17%
Atrial fibrillation 15%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 67 67 $18,829
Sarscv2 vac 30mcg trs-suc im 91320 Office 118 128 $16,819
Vaccine for influenza for injection into muscle 90662 Office 143 144 $11,510

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $152
$152 73 —
VRAYLAR
  • AbbVie, Inc. $108
$108 — —
JARDIANCE
  • Lilly USA, LLC $51
  • Boehringer Ingelheim Pharmaceuticals, Inc. $36
$87 56 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $81
$81 42 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $80
$80 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

406 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record